C4 Therapeutics CCCC Stock
C4 Therapeutics Price Chart
C4 Therapeutics CCCC Financial and Trading Overview
C4 Therapeutics stock price | 1.38 USD |
Previous Close | 3.57 USD |
Open | 3.57 USD |
Bid | 0 USD x 1100 |
Ask | 0 USD x 1800 |
Day's Range | 3.38 - 3.73 USD |
52 Week Range | 2.85 - 13.24 USD |
Volume | 453.06K USD |
Avg. Volume | 586.48K USD |
Market Cap | 177.12M USD |
Beta (5Y Monthly) | 2.097669 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.52 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20 USD |
CCCC Valuation Measures
Enterprise Value | -9712373 USD |
Trailing P/E | N/A |
Forward P/E | -1.2237288 |
PEG Ratio (5 yr expected) | -0.06 |
Price/Sales (ttm) | 6.511537 |
Price/Book (mrq) | 0.67464024 |
Enterprise Value/Revenue | -0.357 |
Enterprise Value/EBITDA | 0.073 |
Trading Information
C4 Therapeutics Stock Price History
Beta (5Y Monthly) | 2.097669 |
52-Week Change | -32.77% |
S&P500 52-Week Change | 20.43% |
52 Week High | 13.24 USD |
52 Week Low | 2.85 USD |
50-Day Moving Average | 3.28 USD |
200-Day Moving Average | 6.43 USD |
CCCC Share Statistics
Avg. Volume (3 month) | 586.48K USD |
Avg. Daily Volume (10-Days) | 619.24K USD |
Shares Outstanding | 49.06M |
Float | 42.52M |
Short Ratio | 4.99 |
% Held by Insiders | 11.31% |
% Held by Institutions | 81.19% |
Shares Short | 3.25M |
Short % of Float | 11.27% |
Short % of Shares Outstanding | 6.61% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -494.074% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -18.42% |
Return on Equity (ttm) | -41.89% |
Income Statement
Revenue (ttm) | 27.2M USD |
Revenue Per Share (ttm) | 0.56 USD |
Quarterly Revenue Growth (yoy) | -50.89% |
Gross Profit (ttm) | -86745000 USD |
EBITDA | -132477000 USD |
Net Income Avi to Common (ttm) | -131335000 USD |
Diluted EPS (ttm) | -2.54 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 270.32M USD |
Total Cash Per Share (mrq) | 5.51 USD |
Total Debt (mrq) | 85.46M USD |
Total Debt/Equity (mrq) | 32.56 USD |
Current Ratio (mrq) | 7.071 |
Book Value Per Share (mrq) | 5.351 |
Cash Flow Statement
Operating Cash Flow (ttm) | -112468000 USD |
Levered Free Cash Flow (ttm) | -69985000 USD |
Profile of C4 Therapeutics
Country | United States |
State | MA |
City | Watertown |
Address | 490 Arsenal Way |
ZIP | 02472 |
Phone | 617 231 0700 |
Website | https://www.c4therapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 146 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Q&A For C4 Therapeutics Stock
What is a current CCCC stock price?
C4 Therapeutics CCCC stock price today per share is 1.38 USD.
How to purchase C4 Therapeutics stock?
You can buy CCCC shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for C4 Therapeutics?
The stock symbol or ticker of C4 Therapeutics is CCCC.
Which industry does the C4 Therapeutics company belong to?
The C4 Therapeutics industry is Biotechnology.
How many shares does C4 Therapeutics have in circulation?
The max supply of C4 Therapeutics shares is 70.99M.
What is C4 Therapeutics Price to Earnings Ratio (PE Ratio)?
C4 Therapeutics PE Ratio is now.
What was C4 Therapeutics earnings per share over the trailing 12 months (TTM)?
C4 Therapeutics EPS is -1.52 USD over the trailing 12 months.
Which sector does the C4 Therapeutics company belong to?
The C4 Therapeutics sector is Healthcare.
C4 Therapeutics CCCC included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ Global Select Market Com NQGS | 8098.63 USD — |
-5.98
|
— — | 8089.65 USD — | 8265.47 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}